Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review
Myriam Marfil-Cantón, Alvaro Prados-Carmona, Marta Cebolla-Verdugo, Husein Husein-ElAhmed, Fernando Campos, Ricardo Ruiz-Villaverde · 2024
Read Anti-OX40 Biological Therapies in the Treatment of Atopic Dermatitis: A Comprehensive Review by Myriam Marfil-Cantón, Alvaro Prados-Carmona, Marta Cebolla-Verdugo, Husein Husein-ElAhmed, Fernando Campos, Ricardo Ruiz-Villaverde (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11594770.txt.
Description
Myriam Marfil-Cantón and co-authors review a new drug family for eczema that blocks the OX40 pathway, in a 2024 paper. Atopic dermatitis is the world's most common inflammatory skin disease, and standard care fails many patients. OX40, a switch on immune cells, has emerged as a driver of the disease.
Antibodies that block OX40 or its partner have shown strong, lasting gains in moderate to severe cases in recent trials. The review lays out how the blockers work and what the trial data show so far. It also weighs where this family fits among newer eczema options. The authors call the approach promising while asking for longer prospective data on safety and durability.
Catalog record
| CREATOR | Myriam Marfil-Cantón, Alvaro Prados-Carmona, Marta Cebolla-Verdugo, Husein Husein-ElAhmed, Fernando Campos, Ricardo Ruiz-Villaverde |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 26 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |